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1. Introduction 
The relationship of specific ligand binding to pos- 
sible changes in antibody conformation remains a con- 
troversial issue. Many investigators have studied ligand 
induced apparent changes in antibody shape by a vari- 
ety of generally indirect methods (reviewed in [4]) in- 
cluding: (i) the optical properties of antibodies or of 
bound ligands [ 1-3, 71, (ii) the susceptibility of anti- 
body-ligand complexes to proteolytic digestion [5, 
61 , (iii) the rate of exchange of labile hydrogens of 
antibody molecules [7, 8] and (iv) sedimentation 
properties of antibodies [9, lo]. In the present exper- 
iments, we have used two immunospecifically purified 
mouse A-myeloma proteins to examine differences in 
the mobility of two spin labeled DNP ligands which 
are approximately the same size, but different in their 
configuration. 
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Our working hypothesis is that the differences in 
configuration of the two spin labels may result in dif- 
ferences in folding of amino acid residues in the active 
sites around the DNP portion as well as the spin label 
moiety of these ligands. Use of the electron spin reso- 
nance (ESR) technique [ 1 l-131 enables us to infer 
differences in the extent folding of the antibody com- 
bining sites from a comparison of the immobilization 
of the spin label portion of the bound ligands. 
2. Material and methods 
Immunospecifically purified A-myeloma proteins 
produced by the mouse plasmacytomas MOPC-3 15 
(Protein-3 15) and MOPC-460 (Protein-460) were ob- 
tained from the pooled serum of BALB/c mice accord- 
ing to the procedure of Eisen et al. [ 171. The DNP 
hydrazone derivative of l-oxyl-2,2,5,5-tetramethyl- 
3-pyrrolidone (I) [ 131 was prepared according to the 
procedure Rozantzev and Neiman [ 141. The N-[ l- 
oxyl-2,2,5,5-tetramethyl3-methyl aminopyrrolidinyl] 
2,4-dinitrobenzene (II) (DNP-methylene-SL(5)) was 
prepared as described previously [ 121 . All ESR spec- 
tra were recorded on a Varian E-6 X-band ESR spec- 
trometer at room temp. or at 4”. The immunoglobulin 
concentrations in buffered saline, pH 7.4, were approx. 
5 x 10W5M and titrations were performed with spin la- 
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Fig.1. Electron spin resonance spectra of spin labeled DNP ligands in the presence of myeloma proteins: DNP-hydrazone-SL(5) 
binding (- ) and DNP-methylene-SL(5) binding (------) by (A) protein-315, and (B) protein-460. The up arrow (t) indicates 
free ligand spectrum and down arrow (1) protein-bound ligand. 
beled ligands such that final ligand concentrations were 
approx. 1 x lo-‘M. Antibody fluorescence quenching 
titrations were performed as described previously [ 131. 
In the ESR and fluorescence quenching titrations 
stock solutions of the spin labeled ligands were pre- 
pared in methanol such that the final ligand addition 
to the solution of myeloma protein in buffered saline 
produced a total concentration of methanol of < 2% 
(v/v). 
3. Results and discussion 
The resonance spectra of antibody-bound and -free 
spin labeled ligands are shown in figs. 1 and 2. The 
high and low field peaks of the free ligand (t) are well 
separated from the broad resonance peaks (4) due to 
immobilization of the spin labeled ligand at the immu- 
noglobulin active site. In a model system, the separa- 
tion of the latter broad peaks, Amax, has been shown 
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Fig.2. Electron spin resonance spectrum of low concentration 
(1 X 10m6M). DNP-methylene-SL(5) in the presence of excess 
protein-460 (5 X lo-‘M) at 4”. The resonance spectrum was 
resolved by accumulating the weak signal eight times on a 
Fabri-Tek 1072 signal averager and the resulting trace dis- 
played on the oscilloscope was photographed using a Polaroid 
camera. Each horizontal division is approx. eight gauss with 
field increasing to the right. 
to be sensitive to changes of the viscosity of the medi- 
um, and therefore, the motional freedom of the spin 
label [ 121 .
Recently we have shown that the differences in 
A max can be used to detect alterations of antibody 
active sites during the immune response [ 131 . Gener- 
ally, a decrease of A,,, from 63 gauss indicates in- 
creasing mobility of the spin label. The A,,, value of 
I [DNP-hydrazone-SL(S)] when bound in the active 
sites of the protein-3 15 was 62.4 + 0.5 gauss, however, 
two peaks were observed when II [DNP-methylene- 
SL(S)] was specifically bound by a separate aliquot of 
the same myeloma protein. The separation of the outer 
peaks was 66.3 f 0.5 gauss and that of the inner peaks 
was 57.3 f 0.5 gauss. A detailed account of the sepa- 
ration of the resonance peaks will be reported in a lat- 
er communication. Nevertheless, these A,,, values in- 
dicate strong interactions of the spin label moiety with 
the immunoglobulin active sites. DNP-hydrazone-SL 
(5) was also found to be strongly immobilized when 
bound in the active sites of the protein-460 (fig. 1B). 
The protein-460 gave an A,,, value of 62.4 f 0.5 
gauss with the binding of DNP-hydrazone-SL(S), but 
no broad resonance peaks could be detected with the 
binding of DNP-methylene-SL(5), although the low 
field peak intensity was higher than the high field peak 
intensity indicating the presence of an asymmetric 
spectrum superimposed on an isotropic free spin la- 
bel spectrum. At lower temperature (4”) when 
1 x 10m6M of II was added to the same concentration 
of protein-460, an intermediately immobilized reso- 
nance spectrum was resolved (fig.2) indicating very 
little interaction of the spin label moiety with the 
immunoglobulin active site. The asymmetric reso- 
nance spectrum observed, at room temp. (fig. 1B dotted 
line spectrum) is due mainly to the binding of the 
DNP portion of the ligand. 
Fig.3 shows the results of the fluorescence quench- 
ing titrations of both myeloma proteins with spin la- 
beled ligands I and II in comparison to fluorescence 
quenching of protein-3 15 by e-DNP-L-lysine and pro- 
tern-460 by 2,4-dinitronaphthol. As was expected, the 
titrations indicated uniform intrinsic binding with the 
spin labeled ligands consistent with the chemical uni- 
formity of these immunoglobulin preparations [ 12, 
15, 161. The most important result of these experi- 
ments is that the two myeloma proteins each bind I 
and II with nearly identical affinities. There are signi- 
ficant differences in the extent of immobilization of 
the two spin labels. Although, there are differences in 
A max values of the resonance spectra of I and II (fig. 
1A) nevertheless, the two ligands are strongly immo- 
bilized at the protein-3 15 binding site. However, the 
resonance spectra in fig.lB indicate that the nitroxide 
moieties of these two ligands have very different mo- 
bility at the protein-460 binding site. Namely, protein- 
460 can immobilize label I but fail to make significant 
contact with the pyrrolidine portion of label II (fig.2). 
These results indicate that the active site of the higher 
affinity protein-3 15 is more flexible or adaptable than 
that of the protein-460 as indicated by their respective 
ability to accommodate the bulky pyrrolidine nitroxide 
labeled ligands. These observations are in accord with 
our previous studies on the binding properties of pri- 
mary and secondary anti-TNP antibodies [ 131. 
Although the two spin labeled ligands used in this 
study have approximately the same size, they differ in 
that the DNP-hydrazoneSL(5) may be a slightly more 
rigid, linear molecule than DNP-methylene-SL(5) due 
to the nature of their respective covalent linkage. One 
would expect that a linear ligand would have less steric 
hindrance and, therefore, greater mobility than a bent 
ligand, if the protein active site interacts only with the 
DNP portion of the ligand. The Amax value of DNP- 
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Fig.3. Fluorescence quenching titrations of 315 protein (left panel) at 25” by spin labels II Co), K = 8.6 X lO’M_’ and I Co), K 
= 4.9 X lO’M_’ and e-DNP-L-lysine (a), K = 4.5 X 106M-i . Fluorescence quenching titrations of 460 protein (right panel) at 3” 
by spin labels I, (0) K = 7.5 X 10sMwl and II Co), K = 5.6 X 105M-’ and 2,4_dinitronaphthol (a), K = 2 X 106MvI-‘. 
hydrazoneSL(5) complex with the protein-460 indi- 
cates that the immunoglobulin active site is large 
enough to accommodate all or part of the spin label 
resulting in strong immobilization (see fig. 1 B). How- 
ever, only very weak immobilization of the spin label 
moiety resulted from the binding of the DNP portion 
of DNP-methyleneSL(5) by the active site of protein- 
460. Fluorescence quenching data indicates that DNP- 
hydrazoneSL(5) has slightly greater affinity to pro- 
tein-460 than DNP-methylene-SL(5). Although it is 
not clear whether the DNP portion of each ligand has 
a similar or identical steric relationship with the active 
site of the protein-460 we have detected that the spin 
label portion located at a fixed distance from the DNP 
group is making extensive contact (DNP-hydrazone- 
SL(5)) or very little contact (DNP-methylene-X(S)) 
with the active site. The large difference in the extent 
of immobilization of these two structurally similar 
ligands at the same antibody active site could result 
from either of two causes: (i) the two ligands are bind- 
ing to different regions of a conformationally rigid ac- 
tive site, or (ii) alternative conformations of the active 
site are selectively stabilized by structurally different 
ligand molecules due to the binding of a particular 
ligand. 
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